Network pharmacological evaluation of strigolactones efficacy as potential inhibitors against therapeutic targets of hepatocellular carcinoma.
Ayush AmodSonu PahalPrincy ChoudharyAyushi GuptaSangeeta SinghPublished in: Biotechnology letters (2022)
Strigol, epistrigol and nijmegen1 could be used as potential inhibitors against HCC and can be further validated through in vitro/in vivo studies.
Keyphrases